Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01480180 · ClinicalTrials.gov registry record · Phase 3

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

A Phase 3 study of Haemophilia A and Congenital Bleeding Disorder, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 3
Development phase
186
Enrollment target
20
Study locations

NCT01480180 is a Phase 3 study of Haemophilia A and Congenital Bleeding Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 186 participants, roughly in line with the 202-participant average among 8 other Haemophilia A trials with a reported enrollment target. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01480180, a Phase 3 study of Haemophilia A and Congenital Bleeding Disorder, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 3
Development phase
186 participants
Enrollment target
20
Study locations

Study Summary

This trial is conducted globally. The aim of the trial is to evaluate the safety and efficacy, including pharmacokinetics (the exposure of the trial drug in the body) of NNC 0129-0000-1003 (N8-GP) in subjects with Haemophilia A.

Conditions Studied

Haemophilia A Congenital Bleeding Disorder

Interventions

  • DRUG turoctocog alfa pegol

Study Locations (20)

California

  • Novo Nordisk Investigational Site - Long Beach
  • Novo Nordisk Investigational Site - Sacramento
  • Novo Nordisk Investigational Site - Torrance

District of Columbia

  • Novo Nordisk Investigational Site - Washington D.C.
  • Novo Nordisk Investigational Site - Washington D.C.

Florida

  • Novo Nordisk Investigational Site - Orlando
  • Novo Nordisk Investigational Site - Tampa

Michigan

  • Novo Nordisk Investigational Site - Detroit
  • Novo Nordisk Investigational Site - East Lansing

New Jersey

  • Novo Nordisk Investigational Site - New Brunswick
  • Novo Nordisk Investigational Site - Newark

Arizona

  • Novo Nordisk Investigational Site - Phoenix

Georgia

  • Novo Nordisk Investigational Site - Augusta

Idaho

  • Novo Nordisk Investigational Site - Boise

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2012-01-30
Est. Completion 2018-12-10
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01480180

The ClinicalTrials.gov registry entry for NCT01480180 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 202-participant average among 8 other Haemophilia A trials with a reported enrollment target. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Haemophilia A appearing as the primary indexed condition, and to 1 intervention - of which turoctocog alfa pegol is the first listed.

NCT01480180 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT01480180 about?

NCT01480180 is a clinical study titled "Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A". This trial is conducted globally. The aim of the trial is to evaluate the safety and efficacy, including pharmacokinetics (the exposure of the trial drug in the body) of NNC 0129-0000-1003 (N8-GP) in subjects with Haemophilia A.

What is the current status of trial NCT01480180?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 2012-01-30. Estimated completion is 2018-12-10.

What conditions does trial NCT01480180 study?

This clinical trial studies the following conditions: Haemophilia A, Congenital Bleeding Disorder.

What interventions are being tested in trial NCT01480180?

The interventions under investigation include: turoctocog alfa pegol (DRUG).

Who is sponsoring clinical trial NCT01480180?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01480180 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Haemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Haemophilia A

All registered trials for this condition

Congenital Bleeding Disorder

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.